HC Wainwright Has Pessimistic View of Neurogene Q2 Earnings

Neurogene Inc. (NASDAQ:NGNE) – HC Wainwright lowered their Q2 2026 EPS estimates for Neurogene in a research note issued on Monday, May 18th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($1.30) for the quarter, down from their previous estimate of ($1.02). The consensus estimate for Neurogene’s current full-year earnings is ($5.54) per share. HC Wainwright also issued estimates for Neurogene’s Q3 2026 earnings at ($1.34) EPS, Q4 2026 earnings at ($1.37) EPS, FY2026 earnings at ($5.39) EPS and FY2027 earnings at ($5.92) EPS.

Several other equities research analysts have also recently weighed in on NGNE. Guggenheim started coverage on shares of Neurogene in a research note on Tuesday, April 28th. They issued a “buy” rating and a $69.00 target price for the company. Canaccord Genuity Group cut their price target on shares of Neurogene to $180.00 and set a “buy” rating for the company in a research note on Monday, April 6th. Lifesci Capital assumed coverage on shares of Neurogene in a research note on Monday, January 26th. They set an “outperform” rating and a $50.00 price target for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Neurogene in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Neurogene presently has a consensus rating of “Moderate Buy” and an average price target of $74.17.

Neurogene Stock Performance

NASDAQ NGNE opened at $26.88 on Wednesday. The firm has a 50-day simple moving average of $24.39 and a 200 day simple moving average of $22.02. Neurogene has a twelve month low of $14.65 and a twelve month high of $37.27. The stock has a market cap of $424.70 million, a PE ratio of -5.91 and a beta of 1.69.

Neurogene (NASDAQ:NGNE) last released its earnings results on Tuesday, May 12th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.09).

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Balyasny Asset Management L.P. acquired a new stake in shares of Neurogene during the third quarter worth approximately $12,114,000. ArrowMark Colorado Holdings LLC increased its holdings in shares of Neurogene by 1.8% during the third quarter. ArrowMark Colorado Holdings LLC now owns 595,839 shares of the company’s stock worth $10,326,000 after buying an additional 10,442 shares in the last quarter. Jennison Associates LLC increased its holdings in shares of Neurogene by 35.3% during the fourth quarter. Jennison Associates LLC now owns 533,088 shares of the company’s stock worth $10,982,000 after buying an additional 138,999 shares in the last quarter. State Street Corp increased its holdings in shares of Neurogene by 47.8% during the fourth quarter. State Street Corp now owns 307,797 shares of the company’s stock worth $6,341,000 after buying an additional 99,487 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Neurogene by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 249,695 shares of the company’s stock worth $5,145,000 after buying an additional 3,262 shares in the last quarter. Institutional investors own 52.37% of the company’s stock.

Insider Transactions at Neurogene

In other Neurogene news, CFO Christine Mikail Cvijic sold 9,600 shares of the firm’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $31.25, for a total transaction of $300,000.00. Following the completion of the transaction, the chief financial officer owned 93,640 shares in the company, valued at $2,926,250. This trade represents a 9.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Stuart Cobb sold 6,797 shares of the firm’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $20.81, for a total transaction of $141,445.57. Following the transaction, the insider owned 30,497 shares of the company’s stock, valued at approximately $634,642.57. This represents a 18.23% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 20,442 shares of company stock valued at $525,622. Corporate insiders own 11.68% of the company’s stock.

Neurogene News Roundup

Here are the key news stories impacting Neurogene this week:

• Negative Sentiment: Q2 2026 EPS to ($1.30) from ($1.02), signaling a worse-than-expected loss outlook.
• Negative Sentiment: Q3 2026 EPS to ($1.34) from ($1.05), another cut to near-term earnings estimates.
• Negative Sentiment: Q4 2026 EPS to ($1.37) from ($1.08), implying continued pressure on earnings into year-end.
• Negative Sentiment: FY2026 EPS to ($5.39) from ($4.16), reflecting a weaker full-year outlook.
• Negative Sentiment: FY2027 EPS to ($5.92) from ($4.93), suggesting losses may remain elevated longer than expected.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.